Non-Alcoholic Fatty Liver Managment
Year: 2025
Type: article
Abstract: Non-alcoholic fatty liver disease (NAFLD) is a common liver condition marked by fat accumulation in the liver without significant alcohol consumption. It ranges from benign non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), a more severe form involving inflammation and cell damage, which can progress to fibrosis, cirrhosis, and liver cancer. NAFLD is closely linked to metabolic syndrome, with key risk factors including obesity, type 2 diabetes, insulin resistance, dyslipidaemia, and sedentary lifestyle. Its pathophysiology involves increased free fatty acid delivery to the liver, insulin resistance, oxidative stress, and inflammation leading to liver damage and fibrosis. Diagnosis typically requires imaging or liver biopsy, while treatment focuses on lifestyle modifications such as weight loss and exercise. Pharmacological options include orlistat, pioglitazone, vitamin E, GLP-1 receptor agonists (e.g., semaglutide), and emerging agents like obeticholic acid and resmetirom. While these treatments can reduce liver fat and inflammation, only resmetirom has shown strong Phase III results for fibrosis improvement. Despite promising therapies, lifestyle change remains the cornerstone of NAFLD management.
Author: Denisha Meghnathi*1, Kiran Rathod2, Chintankumar Tank3, Shivani Herma1, Himanshu Parmar1, Pritesh Odedara1
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6912311867
FWCI:
Cites:
Cited by:
Related to: